VEGFA and colorectal carcinoma: It is the first monoclonal antibody that was approved by the FDA as a second-line treatment for metastatic colorectal cancer 234, 235 and was shown to downregulate the VEGF in human colorectal carcinoma (CRC) cell line and in human CRC mouse xenografts.